Cargando…

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score

BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fati...

Descripción completa

Detalles Bibliográficos
Autores principales: Langlais, Blake T., Mazza, Gina L., Kosiorek, Heidi E., Palmer, Jeanne, Mesa, Ruben, Dueck, Amylou C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577588/
https://www.ncbi.nlm.nih.gov/pubmed/34804309
http://dx.doi.org/10.14740/jh914
_version_ 1784596090313506816
author Langlais, Blake T.
Mazza, Gina L.
Kosiorek, Heidi E.
Palmer, Jeanne
Mesa, Ruben
Dueck, Amylou C.
author_facet Langlais, Blake T.
Mazza, Gina L.
Kosiorek, Heidi E.
Palmer, Jeanne
Mesa, Ruben
Dueck, Amylou C.
author_sort Langlais, Blake T.
collection PubMed
description BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). The original MPN-10 included a fatigue item from the Brief Fatigue Inventory (BFI). The myelofibrosis-specific symptom assessment tool called the MFSAF v4 utilizes a fatigue item developed to be consistent with other items within the SAF. This study sought to validate a modified version of the MPN-10 TSS using the SAF fatigue item for harmonization with MFSAF v4. METHODS: Survey data from two cohorts of patients with essential thrombocythemia, polycythemia vera, or myelofibrosis assessing MPN characteristics and symptom burden were used. RESULTS AND CONCLUSION: BFI and SAF fatigue items were highly correlated in raw score (Pearson r = 0.88), comparable in their severity categorizations (89% agreement for severe versus non-severe) and respective contributions to the TSS (both Cronbach’s alpha = 0.89). Reliability of SAF fatigue was acceptable and independently associated with known disease-related characteristics (splenomegaly, low quality-of-life, and distress). Fatigue in patients with MPNs is measured with high similarity using the SAF fatigue item within the MPN-10 in harmonization with the MFSAF v4.
format Online
Article
Text
id pubmed-8577588
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-85775882021-11-18 Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score Langlais, Blake T. Mazza, Gina L. Kosiorek, Heidi E. Palmer, Jeanne Mesa, Ruben Dueck, Amylou C. J Hematol Original Article BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). The original MPN-10 included a fatigue item from the Brief Fatigue Inventory (BFI). The myelofibrosis-specific symptom assessment tool called the MFSAF v4 utilizes a fatigue item developed to be consistent with other items within the SAF. This study sought to validate a modified version of the MPN-10 TSS using the SAF fatigue item for harmonization with MFSAF v4. METHODS: Survey data from two cohorts of patients with essential thrombocythemia, polycythemia vera, or myelofibrosis assessing MPN characteristics and symptom burden were used. RESULTS AND CONCLUSION: BFI and SAF fatigue items were highly correlated in raw score (Pearson r = 0.88), comparable in their severity categorizations (89% agreement for severe versus non-severe) and respective contributions to the TSS (both Cronbach’s alpha = 0.89). Reliability of SAF fatigue was acceptable and independently associated with known disease-related characteristics (splenomegaly, low quality-of-life, and distress). Fatigue in patients with MPNs is measured with high similarity using the SAF fatigue item within the MPN-10 in harmonization with the MFSAF v4. Elmer Press 2021-10 2021-10-31 /pmc/articles/PMC8577588/ /pubmed/34804309 http://dx.doi.org/10.14740/jh914 Text en Copyright 2021, Langlais et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Langlais, Blake T.
Mazza, Gina L.
Kosiorek, Heidi E.
Palmer, Jeanne
Mesa, Ruben
Dueck, Amylou C.
Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title_full Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title_fullStr Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title_full_unstemmed Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title_short Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
title_sort validation of a modified version of the myeloproliferative neoplasm symptom assessment form total symptom score
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577588/
https://www.ncbi.nlm.nih.gov/pubmed/34804309
http://dx.doi.org/10.14740/jh914
work_keys_str_mv AT langlaisblaket validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore
AT mazzaginal validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore
AT kosiorekheidie validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore
AT palmerjeanne validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore
AT mesaruben validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore
AT dueckamylouc validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore